Research Paper
Role of Pentoxifylline in Oral Submucous Fibrosis: A clinical trial
Author: Dr. Amber Kesarwani*, Dr. Rajesh Kumar**,
*Postgraduate Resident, Department of ENT, IMS, BHU, Varanasi,
Email id: dramber.kesar@gmail.com
**Associate Professor, Department of ENT, IMS, BHU, Varanasi
Download PDF
Abstract:
Aims:
Oral submuco
us fibrosis
(OSMF) is
a well-recognized potentially malignant condition of unknown
aetiology
.
This clinical trial was done to evaluate the effectiveness of Pentoxifylline in OSMF and study of its side effects.
Materials and Methodology: This clinical trial was done in Department of E.N.T., I.M.S.-B.H.U. on 75 patients which were divided in two groups. Group I consists of 50 patients who were given oral Pentoxifylline at a dose of 400 mg TDS for 6 months while Group II included 25 patients which served as Control group (age and sex matched) who were given multivitamins. All the patients were asked to quit substance abuse and were taught jaw dilator exercises. Follow up record was maintained at 1st, 3rd and 6th month of beginning of treatment. Observations and Results: Significantimprovement in patients receiving Tab. Pentoxifylline was observed. Total improvement in symptoms score is 89.7% after 6 months of treatment in Group I while in Group II it was just 43.5% (p<0.05).
The trismus improved by 5.46 mm in group I and 1.36 mm in group II (p<0.05).
Conclusion: Pentoxifylline is effective in alleviating symptoms and signs of OSMF from the preliminary data. However, long term administration and side effects may decrease its compliance in patients.
Keywords:
Oral Submucous Fibrosis, Pentoxifylline, Trismus
